Tyrosine monitoring in children with early and continuously treated phenylketonuria: Results of an international practice survey

Journal of Inherited Metabolic Disease

Volumn 33, Issue SUPPL. 3, 2010, Pages

  Sharman, Rachael ^a   Sullivan, Karen A ^a   Young, Ross Mcd ^a   McGill, James J ^b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PHENYLALANINE; TYROSINE;

ADOLESCENT; AUSTRALIA AND NEW ZEALAND; BLOOD; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; DIET SUPPLEMENTATION; EUROPE; EXECUTIVE FUNCTION; HEALTH CARE SURVEY; HUMAN; INFANT; INTELLIGENCE TEST; METABOLISM; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; NEWBORN; NORTH AMERICA; PHENYLKETONURIAS; PREDICTIVE VALUE; PRESCHOOL CHILD; PSYCHOLOGY; QUESTIONNAIRE; TIME; TREATMENT OUTCOME; ARTICLE; PHENYLKETONURIA; PSYCHOLOGICAL ASPECT;

ADOLESCENT; AUSTRALASIA; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COGNITION; DIETARY SUPPLEMENTS; EUROPE; EXECUTIVE FUNCTION; HEALTH CARE SURVEYS; HUMANS; INFANT; INFANT, NEWBORN; INTELLIGENCE TESTS; NEUROPSYCHOLOGICAL TESTS; NORTH AMERICA; PHENYLALANINE; PHENYLKETONURIAS; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 84897924606     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9211-6     Document Type: Article

References (18)

1. Antshel KM, Waisbren SE (2003) Timing is everything: executive functions in children exposed to elevated levels of phenylalanine. Neuropsychology 17:458-468
2. Arnold GL, Vladutiu CJ, Orlowski CC, Blakely EM, DeLuca J (2004) Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 27:137-143
3. Australian Society for Inborn Errors of Metabolism (2005) The PKU handbook. Human Genetic Society of Australia, Alexandra
4. Burgard P (2000) Development of intelligence in early treated phenylketonuria. Eur J Ped 159(Suppl 2):74-79
5. Chace DH, Sherwin JE, Hillman SL, Lorey F, Cunningham GC (1998) Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens. Clin Chem 44:2405-2409
6. Diamond A, Prevor MB, Callender G, Druin DP (1997) Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev 62:i-iv
7. Hilton MA, Sharpe JN, Hicks LG, Andrews BF (1986) A simple method of detection of heterozygous carriers of the gene for classic phenylketonuria. J Pediatr 109:601-604
8. Huijbregts SC, de Sonneville LM, van Spronsen FJ, Licht R, Sergeant JA (2002a) The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory. Neurosci Biobehav Rev 26:697-712
9. Huijbregts SC, de Sonneville LM, Licht R, van Spronsen FJ, Verkerk PH, Sergeant JA (2002b) Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 40:7-15
10. Luciana M, Sullivan J, Nelson CA (2001) Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev 72:1637-1653
11. National Institutes of Health (2000) NIH consensus panel recommends comprehensive approach to life long care for PKU. http://www.nichd.nih.gov/news/ releases/pku.cfm. Accessed July 9, 2010
12. Posner J, Gorman D, Nagel BJ (2009) Tyrosine supplements for ADHD symptoms with comorbid phenylketonuria. J Neuropsychiatry Clin Neurosci 21:228-230
13. Poustie VJ, Rutherford P (1999) Tyrosine supplementation for phenylketonuria. Cochrane Database Syst Rev 8:CD001507
14. Sharman R, Sullivan K, Young R, McGill J (2009) Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria. Clin Genet 75:169-174
15. Sharman R, Sullivan K, Young R, McGill J (2010) A preliminary investigation of the role of the phenylalanine:tyrosine ratio in children with early and continuously treated phenylketonuria: toward identification of "safe" levels. Dev Neuropsychol 35:57-65
16. van Spronsen FJ, van Rijn M, Bekhof J, Koch R, Smit PG (2001) Phenylketonuria: tyrosine supplementation in phenylalaninerestricted diets. Am J Clin Nutr 73:153-157
17. van Spronsen FJ, Ahring KK, Gizewska M (2009) PKU-what is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders. J Inherit Metab Dis 32:58-64
18. Waisbren SE, Noel K, Fahrbach K et al. (2007) Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-Analysis. Mol Genet Metab 92:63-70